Generate Biomedicines (GENB) Q2 2026 earnings summary

Executive summary

• Clinical-stage biotech focused on AI-driven drug discovery, with no approved products and ongoing global Phase 3 trials for GB-0895 in severe asthma, Phase 1 for GB-4362 in oncology, and planned Phase 1 for GB-5267 in 2026.

• Closed IPO in March 2026, raising $369.3M, and converted all preferred stock to common stock.

• Collaboration agreements with Novartis and Amgen provide milestone and royalty opportunities, with Novartis advancing an AI-enabled biologic into its preclinical pipeline.

• Presented Phase 1b data for GB-0895 in COPD and initiated first cohort dosing for GB-4362 (MMAE neutralizer) in oncology.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $457.4M as of June 30, 2026, down from $516.6M as of March 31, 2026.

• Net loss attributable to common stockholders was $67.3M for Q2 2026 and $128.7M for the first half of 2026, compared to $52.4M and $94.1M for the same periods in 2025.

• Collaboration revenue declined to $6.3M in Q2 2026 from $10.1M in Q2 2025, and to $13.5M for the first half of 2026 from $18.9M in 2025.

• Operating expenses increased to $77.9M in Q2 2026 (from $70.3M) and $149.3M for the first half (from $127.3M), driven by higher R&D and G&A costs.

• R&D expenses rose to $64.3M in Q2 2026 (from $59.7M), mainly due to increased spending on GB-0895 and personnel.

• General and administrative expenses increased to $13.6M in Q2 2026 (from $10.5M), primarily due to higher stock-based compensation and professional fees.

Outlook and guidance

• Current cash resources expected to fund operations into the first half of 2028; additional capital will be needed for long-term operations.

• No product revenue expected for several years; future revenue dependent on successful clinical development and regulatory approval.

• Expenses and operating losses anticipated to increase as clinical and preclinical programs expand.

• Continued focus on advancing internal pipeline, executing collaborations, and entering new partnerships.